2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multicenter Clinical Evaluation of the Revogene Strep A Molecular Assay for Detection of Streptococcus pyogenes from Throat Swab Specimens

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Group A streptococcus (GAS) species cause bacterial pharyngitis in both adults and children. Early and accurate diagnosis of GAS is important for appropriate antibiotic therapy to prevent GAS sequalae. The Revogene Strep A molecular assay (Meridian Bioscience Canada Inc, Quebec City, QC, Canada) is an automated real-time PCR assay for GAS detection from throat swab specimens within approximately 70 min. This multicenter prospective study evaluated the performance of the Revogene Strep A molecular assay compared to that of bacterial culture.

          ABSTRACT

          Group A streptococcus (GAS) species cause bacterial pharyngitis in both adults and children. Early and accurate diagnosis of GAS is important for appropriate antibiotic therapy to prevent GAS sequalae. The Revogene Strep A molecular assay (Meridian Bioscience Canada Inc, Quebec City, QC, Canada) is an automated real-time PCR assay for GAS detection from throat swab specimens within approximately 70 min. This multicenter prospective study evaluated the performance of the Revogene Strep A molecular assay compared to that of bacterial culture. Dual throat swab specimens in either liquid Amies or Stuart medium were collected from eligible subjects (pediatric population and adults) enrolled across 7 sites (USA and Canada). Revogene Strep A and reference testing was performed within 7 days and 48 h of sample collection, respectively. Of the 604 evaluable specimens, GAS was detected in 154 (25.5%) samples by the reference method and in 175 (29%) samples by the Revogene Strep A assay. Revogene Strep A assay sensitivity and specificity were reported to be 98.1% (95% confidence interval [CI], 94.4 to 99.3) and 94.7% (95% CI, 92.2 to 96.4), respectively. The positive predictive value was 86.3% (95% CI, 80.4 to 90.6), negative predictive value was 99.3% (95% CI, 98.0 to 99.8) with a 1.0% invalid rate. Discrepant analysis with alternative PCR/bidirectional sequencing was performed for 24 false-positive (FP) and 3 false-negative (FN) specimens. Concordant results were reported for 17 (FP only) of 27 discordant specimens. The Revogene Strep A assay had high sensitivity and specificity for GAS detection and provides a faster alternative for GAS diagnosis.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          The global burden of group A streptococcal diseases.

          The global burden of disease caused by group A streptococcus (GAS) is not known. We review recent population-based data to estimate the burden of GAS diseases and highlight deficiencies in the available data. We estimate that there are at least 517,000 deaths each year due to severe GAS diseases (eg, acute rheumatic fever, rheumatic heart disease, post-streptococcal glomerulonephritis, and invasive infections). The prevalence of severe GAS disease is at least 18.1 million cases, with 1.78 million new cases each year. The greatest burden is due to rheumatic heart disease, with a prevalence of at least 15.6 million cases, with 282,000 new cases and 233,000 deaths each year. The burden of invasive GAS diseases is unexpectedly high, with at least 663,000 new cases and 163,000 deaths each year. In addition, there are more than 111 million prevalent cases of GAS pyoderma, and over 616 million incident cases per year of GAS pharyngitis. Epidemiological data from developing countries for most diseases is poor. On a global scale, GAS is an important cause of morbidity and mortality. These data emphasise the need to reinforce current control strategies, develop new primary prevention strategies, and collect better data from developing countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America.

            The guideline is intended for use by healthcare providers who care for adult and pediatric patients with group A streptococcal pharyngitis. The guideline updates the 2002 Infectious Diseases Society of America guideline and discusses diagnosis and management, and recommendations are provided regarding antibiotic choices and dosing. Penicillin or amoxicillin remain the treatments of choice, and recommendations are made for the penicillin-allergic patient, which now include clindamycin.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America

              Abstract The guideline is intended for use by healthcare providers who care for adult and pediatric patients with group A streptococcal pharyngitis. The guideline updates the 2002 Infectious Diseases Society of America guideline and discusses diagnosis and management, and recommendations are provided regarding antibiotic choices and dosing. Penicillin or amoxicillin remain the treatments of choice, and recommendations are made for the penicillin-allergic patient, which now include clindamycin.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                J Clin Microbiol
                J. Clin. Microbiol
                jcm
                jcm
                JCM
                Journal of Clinical Microbiology
                American Society for Microbiology (1752 N St., N.W., Washington, DC )
                0095-1137
                1098-660X
                22 April 2020
                24 June 2020
                July 2020
                24 June 2020
                : 58
                : 7
                : e01775-19
                Affiliations
                [a ]Children’s Mercy Hospital, Kansas City, Missouri, USA
                [b ]Indiana University School of Medicine, Indianapolis, Indiana, USA
                [c ]Wayne State University School of Medicine, Detroit, Michigan, USA
                [d ]Valley Children’s Hospital, Fresno, California, USA
                [e ]BC Children’s and Women’s Hospital, Vancouver, British Columbia, Canada
                [f ]Centre de Recherche Saint-Louis, Quebec City, Canada
                [g ]Medical College of Wisconsin, Milwaukee, Wisconsin, USA
                [h ]Microbiology Specialists Inc., Houston, Texas, USA
                bioMérieux
                Author notes
                Address correspondence to R. Selvarangan, rselvarangan@ 123456cmh.edu .

                Citation Banerjee D, Michael J, Schmitt B, Salimnia H, Mhaissen N, Goldfarb DM, Lachance P, Faron ML, Aufderheide T, Ledeboer N, Weissfeld A, Selvarangan R. 2020. Multicenter clinical evaluation of the Revogene Strep A molecular assay for detection of Streptococcus pyogenes from throat swab specimens. J Clin Microbiol 58:e01775-19. https://doi.org/10.1128/JCM.01775-19.

                Article
                01775-19
                10.1128/JCM.01775-19
                7315036
                32321780
                04f30fdb-7e66-486b-9fb3-4f4793f24b1d
                Copyright © 2020 Banerjee et al.

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

                History
                : 12 November 2019
                : 26 December 2019
                : 14 April 2020
                Page count
                Figures: 0, Tables: 3, Equations: 0, References: 26, Pages: 6, Words: 4573
                Funding
                Funded by: Meridian Bioscience Canada Inc;
                Award Recipient :
                Categories
                Bacteriology
                Custom metadata
                July 2020

                Microbiology & Virology
                clinical trial,group a streptococcus,molecular assay,multicenter
                Microbiology & Virology
                clinical trial, group a streptococcus, molecular assay, multicenter

                Comments

                Comment on this article